Ganciclovir prophylaxis of cytomegalovirus disease.
Conti
D J
DJ
Department of Surgery, Albany Medical College, New York 12208, USA.
Shen
G
G
Singh
T
T
Isenberg
A
A
Freed
B M
BM
D000328:Adult; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D015774:Ganciclovir / Q000191:economics / Q000627:therapeutic use*; D006084:Graft Rejection / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009518:New York; D011183:Postoperative Complications / Q000517:prevention & control*; D012307:Risk Factors; D015996:Survival Rate
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D015774:Ganciclovir